Jorge Santiago-Ortiz
VP, CMC & Regulatory Affairs,
Apertura Gene Therapy
Sessions
-
08-Sep-2026Theatre 1 (Zafir)Spotlight: : Enabling IV, brain-wide AAV gene delivery through an FDA-informed, GMP-ready platform
-
08-Sep-2026Theatre 1 (Zafir)Fireside chat: AAV at scale without compromise: How the field is fixing manufacturing bottlenecks and toxicity risk without slowing clinical momentum